Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Craig N. Robinson who wrote (375)	5/9/2001 12:44:31 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 668

Curis Inc. 1Q Losses 57c A Share Vs 16c Dow Jones Newswires Curis Inc. - Cambridge, Mass. 1st Quar March 31: 2001 2000 Revenues $249,165 $670,387 Net income a (17,807,229) (5,841,548) Avg shrs 31,434,120 37,556,903 Shr earns (basic) Net income a (.57) (.16) Shr earns (diluted) Net income a (.57) (.16) Figures in parentheses are losses. a. Includes amortization of intangibles and stock-based compensation totaling $9.7 million. Excluding the items, the company lost $8.2 million, or 26 cents a share. Curis Inc. (CRIS) reported that due to a July merger, comparison to the 2000 period may not accurately reflect the change in the company's operations. Curis, which was formed by the merger of Creative Biomolecules Inc., Ontogeny Inc. and Reprogenesis Inc., develops regenerative medicine products. Company Web site: curis.com